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Although unusual in western countries and in Australia in
general, post-streptococcal glomerulonephritis (PSGN) is still
common in Australian Aboriginal children living in remote
communities. Here, we evaluated whether episodes of
acute PSGN increased the risk for chronic kidney disease in
later life in 1519 residents of a remote Aboriginal community
(85% of those age eligible), with high rates of renal and
cardiovascular disease, who participated in a health screen
over a 3-year period. Of these, 200 had had at least one
episode of PSGN, with 27 having had multiple episodes,
usually in childhood. High levels of albuminuria (albumin/
creatinine ratio) with increasing age were confirmed. All
PSGN episodes were associated with group A streptococcal
skin infections, often related to scabies. In both genders,
aged 10–39 years at screening, about one in five had such a
history. Among them, PSGN (5 years or more earlier) was
significantly associated with higher levels of albuminuria
than those without. In women, aged 30–39 years, a history
of PSGN was associated with a significantly higher frequency
of estimated glomerular filtration rates o60ml/min. The
adjusted odds ratios for an albumin/creatinine ratio over
34g/mol (overt albuminuria) in males and females with a
history of PSGN were 4.6 and 3.1, respectively, compared
with those without a history. Thus, PSGN contributes to the
very serious burden of chronic kidney disease in this
community. Rigorous strategies to prevent scabies and
Group A streptococcal infections will reduce this burden.
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Although now unusual in western countries and in Australia
in general,1 post-streptococcal glomerulonephritis (PSGN)
is still common in Australian Aboriginal children living in
remote communities,2–5 where scabies is common and group
A streptococcal pyoderma is endemic. PSGN occurs in both
sporadic and epidemic forms. In these communities, chronic
renal disease and end-stage renal failure also occur in adults
at alarming rates.6,7
PSGN is usually followed by clinical recovery over several
days to weeks, and the long-term outlook has generally
been regarded as excellent, with no increase in risk of urinary
abnormalities or hypertension.8–10 However, some studies
have suggested that there is an increase in chronic renal
impairment after this illness.11,12
In one high-risk Aboriginal community, we described
persisting urine abnormalities among 62 children who had
symptomatic PSGN during specific epidemics in the 1980s,4
and higher rates of microalbuminuria in people with a clinical
history of PSGN at ages 15–29 years.13 We now evaluate in
that same community, the association of documented episodes
of PSGN with albuminuria during a second community-wide
study conducted from 2004 to 2006, or 410 years later.
RESULTS
A total of 1519 people participated in the screening program,
or about 85% of the age-eligible population. Of these, 200
people had a history of PSGN recorded in their clinical
charts: 173 had a single episode and 27 had two or more
episodes. Figure 1 shows the timing of those episodes, all
of which had been documented since 1970. There were
major epidemics in the early 1980s and in 1987, and smaller
epidemics in 1994, 1999/2000, and in 2005, as well as sub-
stantial numbers of endemic cases throughout. There is lim-
ited information on streptococcal serotypes before the year
2000, but many cases were emm55 by anecdotal recall. In the
year 2000, recorded serotypes in cases included emm49.4,
emm95, and emm86. In 2001, one case was emm1105, and in
2005 cases were mostly emm55 (Catherine Marshall and Bart
Currie, Menzies School of Health Research, personal com-
munication). Table 1 shows the numbers and proportions of
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people by sex and age group who had such a history. In all,
16.5% (N¼ 92) of male participants and 19% of female
participants (N¼ 85) aged 5–39 years had a documented
history of PSGN. Rates in people agedX40 years at screening
were lower than in younger people, and above they were
excluded from further analyses.
Participants were then restricted to those aged 10–39 years
at examination, with albumin/creatinine ratio (ACR) values
available on the community screen. Those without a PSGN
history were compared with those with a PSGN history
recordedX5 years before the examination. These constituted
969 persons, of whom 177 (18.7%) had a PSGN history,
X5 years earlier—16.5% of male participants and 20.7%
of female participants—as shown in Table 2. The table also
shows that the PSGN episodes had usually occurred in
childhood. The average time since the episodes for those aged
20–29 years at screening was about 18 years, and for those
who were 30–39 years old at screening it was 25 years.
Table 3 compares some characteristics of those without
and with a remote history of PSGN. Those with a PSGN
history were somewhat older, on average, compatible with
the major epidemics in the 1980s. There were no significant
differences between the groups in body mass index, blood
pressure, C-reactive protein, or lipid levels (apart from a
lower low-density lipoprotein level in men with a PSGN
history). Those with PSGN tended toward higher rates of
diabetes than those without; however, this was not significant
with adjustment for age, and hemoglobin A1c levels were not
different. Among the ‘renal’ indicators, average serum
creatinine levels were higher in women with a remote history
of PSGN than in those without. In addition, people with a
PSGN history tended toward higher rates of hematuria, had
significantly higher rates of proteinuria determined by
dipstick method, had higher mean ACR levels, and were
more likely to have ‘elevated’ levels of ACR by category
than those without a PSGN history. It is noteworthy that
most individuals with high ACR levels (X34 mg/mmol)
also had proteinuria, i.e., 81% of men and 93% of women,
with Po0.0001 for the association between the two in both
sexes.
Table 4 shows trends toward higher ACRs in those with
a remote PSGN history by age group and gender. There
were no differences in estimated glomerular filtration rate
(eGFR) according to PSGN history in any age group in
men, and none had eGFR o60. However, in women
aged 30–39 years, there was a trend toward lower eGFRs in
those with a PSGN history, and 12% of that group had
‘low’ GFR levels, compared with none without such a history
(P¼ 0.0003).
Figure 2 compares the distribution of ACR according to a
remote PSGN history in both men and women. In all groups,
those with PSGN had a broader distribution of ACR values
than those without, and the mean values were notably higher
in those with PSGN in the two older age groups. Figure 3
also shows the higher average values of ACR in the PSGN
groups. Figure 4 shows trends toward higher categories of
ACR in those with PSGN in both the sexes across all age
groups.
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Figure 1 | Episodes of post-streptococcal glomerulonephritis
(PSGN) since 1970 by year of occurrence.
Table 1 | Distribution of people with a history of PSGN, by age
and sex
Age group (years) Males Females
5–9 9/70 (12.9%) 4/79 (5.1%)
10–19 23/170 (13.5%) 21/141 (14.9%)
20–29 35/220 (15.9%) 37/139 (26.2%)
30–39 38/176 (21.6%) 34/145 (23.4%)
40+ 9/174 (5.2%) 5/205 (2.4%)
Abbreviation: PSGN, post-streptococcal glomerulonephritis.
Table 2 | Descriptive statistics for people with a remote
history of PSGN (X5 years prior)
Age group
(years)
PSGN
(N)
Age at PSGN (years):
mean (s.d.), range
Time since PSGN (years):
mean (s.d.), range
Males
10–19 20 5.1 (2.9), 0.9–10.5 11.7 (4.2), 5.3–18.7
20–29 35 6.7 (3.8), 2.2–22.3 17.9 (4.0), 7.3–24.8
30–39 37 10.0 (4.1), 0.3–22.3 24.2 (3.1), 11.7–35.0
Females
10–19 16 4.9 (2.8),1.3–11.3 10.7 (2.9), 5.4–16.6
20–29 36 7.2 (3.8), 0.02–15.4 18.3 (4.4), 10.8–29.0
30–39 33 11.5 (6.7), 5.1–33.8 22.4 (6.2), 5.6–32.2
Abbreviation: PSGN, post-streptococcal glomerulonephritis.
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Table 5 summarizes the risk exacerbations for albuminuria
above the microalbuminuria threshold (ACR X3.4), and
above the overt albuminuria threshold (ACRX34) according
to a remote history of PSGN, adjusted for age. A history
of PSGN was associated with an almost threefold increase
in rates of ACR X3.4 and a 4threefold increase in overt
albuminuria in men, and with more than twofold increases
of each in women. The strength of these associations was
unchanged or strengthened with adjustment for body mass
index, blood pressure, and diabetes.
Among people who were 20–39 years old at screening,
neither the time since the PSGN episode nor the age at the
PSGN episode were significant determinants of renal
function at screening.
DISCUSSION
Documented episodes of PSGN, both epidemic and sporadic,
have been very common since 1970 in this Aboriginal group.
In the mid 2000s, about 15% of adolescents (10–19 years of
age) and more than 20% of young adults (20–39 years of age)
had such a history recorded, with women equally or more
often affected than men. In both the sexes, those with a
history of PSGN 5 or more years earlier, in whom acute
inflammatory effects of PSGN should have subsided, had
higher average levels of ACR than those without a PSGN
history, and were 3–4 times more likely to have elevated levels
of ACR at the microalbuminuria and the overt albuminuria
cutoffs. They also tended toward higher rates of proteinuria
and hematuria determined by dipstick method. In addition,
Table 3 | Characteristics of subjects by a remote history of PSGN (X5 years prior) by sex
Males Non PSGN (N=465) PSGN (N=92) P-value
Age (years) 24.7 (8.6) 27.6 (7.2) 0.02
BMI (kg/m2) 21.4 (5.0) 21.0 (3.8) 0.14
SBP (mmHg) 116.8 (15.2) 117 (14.0) 0.55
DBP (mmHg) 72.1 (11.7) 72.2 (11.4) 0.28
S creatinine (mmol/l)a 81.4 (19.0) 82.1 (12.3) 0.93
HDL (mmol/l)b 1.3 (0.3) 1.3 (0.3) 0.12
LDL (mmol/l)b 2.7 (0.8) 2.4 (0.9) 0.02
Trigs (mmol/l)b 1.6 (1.2) 1.8 (1.7) 0.11
CRP (mg/l)b 6.8 (11.3) 5.5 (5.3) 0.30
HbA1c (%)b 5.7 (0.5) 5.7 (0.5) 0.98
Diabetesc 3.4 (2.0,5.5) 7.6 (3.1–15.1) 0.24
Proteinuria X1+ c 20.2 (16.7–24.2) 27.2 (18.4–37.4) 0.31
Hematuria Xsmallc 7.1 (4.9–9.8) 13.0 (6.9–21.7) 0.04
uACR (mg/mmol)d 1.50 (1.3–1.7) 2.95 (2.1–4.2) 0.002
ACRco3.4 80 (76.1–83.6) 57.6 (46.9–67.9) 0.001
3.4–33 16.5 (13.3–20.2) 30.4 (21.3–40.9)
34+ 3.4 (2.0–5.5) 12 (6.1–20.4)
Females Non PSGN (N=325) PSGN (N=85) P-value
Age (years) 24.5 (8.9) 27.2 (6.8) 0.01
BMI (kg/m2) 22.9 (6.5) 24.3 (6.3) 0.59
SBP (mmHg) 110.9 (13.3) 112.4 (14.1) 0.81
DBP (mmHg) 71 (10.7) 72 (10.3) 0.88
S creatinine (mmol/l)a 56.6 (9.7) 61.2 (24.5) 0.01
HDL (mmol/l)b 1.3 (0.3) 1.3 (0.4) 0.82
LDL (mmol/l)b 2.4 (0.7) 2.4 (0.8) 0.74
Trigs (mmol/l)b 1.6 (1.4) 1.9 (1.6) 0.20
CRP (mg/l)b 9.2 (9.8) 9.4 (10.2) 0.88
HbA1c (%)b 6.0 (1.1) 6.1 (1.3) 0.66
Diabetesc 11.1 (7.9–15.0) 15.3 (8.4–24.7) 0.85
ProteinuriaX1+c 18.0 (14.1–22.8) 32.9 (23.1–44.0) 0.02
HematuriaXsmallc 11.5 (8.1–15.3) 18.8 (11.2–28.8) 0.07
uACR (mg/mmol)d 2.8 (2.4–3.3) 6.5 (4.2–10.1) 0.005
ACRco3.4 66.3 (60.8–71.4) 43.5 (32.8–54.7) 0.002
3.4–33 25.2 (20.5–30.2) 34.1 (24.2–45.2)
34+ 8.6 (5.8–12.2) 22.4 (14.0–32.7)
Abbreviations: ACR, albumin/creatinine ratio; BMI, body mass index; CRP, C-reactive protein; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HbA1c,
hemoglobin A1c; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; PSGN, post-streptococcal glomerulonephritis; S creatinine, serum
creatinine; SBP, systolic blood pressure; uACR, urine albumin-to-creatinine ratio.
Mean (s.d.) except where otherwise specified. All P-values reported are adjusted for age.
aMales: N=398 non-PSGN, 87 PSGN; females: N=266 non-PSGN, 83 PSGN.
bMales: a minimum of 397 non-PSGN and 83 PSGN; females: a minimum of 258 non-PSGN and 79 PSGN.
c% (95% CI).
dGeometric mean (95% CI).
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12% of women between 30 and 39 years of age with a remote
PSGN history had low levels of eGFR by the standard
definition.
Thus, PSGN contributes to the burden of CKD in this
community. In view of the powerful predictive value of
baseline levels of albuminuria for CKD progression and for
Table 4 | Renal parameters by a remote history of PSGN (X5 years prior) by sex and age group (number of participants in
italics)
Urine ACRa eGFR (MDRD)b eGFRo60c
Age No PSGN PSGN No PSGN PSGN No PSGN PSGN
Males (years)
10–19 1.0 (0.9–1.1) 146 1.3 (0.7–2.4) 20 147.0 (46.7) 85 130.1 (21.8) 17 0 (0–4.2)d 85 0 (0–20)d 17
20–29 1.1 (1.0–1.3) 182 2.9 (1.6–5.2) 35 105.5 (16.2) 179 106.0 (19.6) 34 0 (0–2.0)d 179 0 (0–10)d 34
30–39 3.4 (2.6–4.5) 138 4.7 (2.7–8.2) 37 99.4 (19.8) 134 98.3 (15.1) 36 1.5 (0.2–5.3) 134 0 (0–10)d 36
Females (years)
10–19 1.5 (1.3–1.8) 117 2.2 (0.9–5.5) 16 146.8 (30.9) 58 137.3 (24.2) 14 0 (0–6.2)d 58 0 (0–23.2)d 14
20–29 2.3 (1.8–2.9) 99 4.9 (2.5–9.5) 36 125.6 (24.9) 99 125.0 (27.1) 36 0 (0–3.7)d 99 0 (0–10)d 36
30–39 6.4 (4.6–8.8) 110 14.8 (7.2–30) 33 110.8 (21.9) 109 106.8 (33.0) 33 0 (0–3.2)d 109 12.1 (3–28) 33
Abbreviations: ACR, albumin/creatinine ratio; eGFR, estimated glomerular filtration rate; MDRD, Modification of Diet in Renal Disease equation; PSGN, post-streptococcal
glomerulonephritis.
aUrine ACR: gm/mol, geometric mean (95% CI).
beGFR, arithmetic mean (s.d.).
ceGFR o60, percent (CI).
dOne-sided, 97.5% CI.
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Figure 2 |Albumin/creatinine ratio (ACR) levels by sex and age group according to a remote history of post-streptococcal
glomerulonephritis (PSGN; X5 years prior).
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Figure 3 |Albumin/creatinine ratio (ACR) levels by sex and age group according to a remote history of post-streptococcal
glomerulonephritis (PSGN; X5 year prior). CI, confidence interval.
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both nonrenal and renal deaths,14,15 it must also contribute
to this community’s high rates of renal failure and premature
nonrenal mortality.
The findings are consistent with the higher prevalence of
microalbuminuria documented410 years earlier in the same
community in people aged 15–29 years with a recorded PSGN
history.13 They are also compatible with a case–control study
showing high levels of albuminuria in the children who had
had PSGN during the 1980s epidemics.4 The current study
adds value in the embrace of all recorded episodes of PSGN
between 1970 and 2005; in the greater number of people with
PSGN examined, in specification of aX5-year interval to define
delayed sequelae of PSGN, and the more advanced age (X10
years greater) of the older participants. In an environment
where ACR levels increase with age,13 the progression into
adult life of people who had episodes of PSGN in childhood
allows more fulsome expression of its renal-damaging effects.
It particularly illuminated the association of a remote history
of PSGN with higher rates of overt albuminuria, whose role
as a marker of kidney disease and predictor of renal and
nonrenal death is now incontrovertible.13–15 The demonstra-
tion of lower GFRs in some individuals with a PSGN history,
specifically in women aged 30–39 years, is also new.
Thus, our knowledge of the long-term sequelae of PSGN
is expanded.1,8–12,16–21 Demonstration in other settings of
a reduced renal functional reserve supports such an asso-
ciation.22,23 The data suggest that, in some people, kidney
damage persists or is superimposed years after acute PSGN
episodes. Persisting or secondary inflammation, as well as
hyperperfusion or hypertrophy of the remaining nephrons/
glomeruli following loss of a critical number of nephrons
could be among the mechanisms.24 Kidney biopsy data in this
and other remote Aboriginal settings are supportive, showing
high rates of post-infectious GN and glomerulomegaly, which
presumably marks compensatory hypertrophy.25,26
Strengths of this study include the excellent ascertainment
in the screen, the availability of the clinical records, the sweep
of the historical information over 35 years, and the detailed
knowledge of the distribution, associations, and natural
history of renal disease in this community.13–15 The striking
frequency of PSGN and the high density of other nephro-
pathic factors in this environment have probably helped educe
the phenomenon. Weaknesses include the variable sensitivity
to PSGN episodes over time; failure to detect some cases of
PSGN have probably resulted in underascertainment of its
contribution to CKD. In hindsight, health workers comment
that, in non-epidemic years and in the lead-up to recognized
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Figure 4 |Albumin/creatinine ratio (ACR) categories by sex and age group according to a remote history of post-streptococcal
glomerulonephritis (PSGN; X5 years prior).
Table 5 | Odds ratios (95% CI) for renal parameters by history
of remote PSGN (X5 years prior) in people aged 10–39 years
at screening
Renal outcome
ACRX3.4 ACRX34
Males
Adjusted for age 2.88 (1.7–4.8) 3.52 (1.5–8.0)
Adjusted for age, BMI, SBP,
DBP, diabetes
3.22 (1.9–5.6) 4.96 (1.9–12.6)
Females
Adjusted for age 2.26 (1.4–3.8) 2.86 (1.5–5.6)
Adjusted for age, BMI, SBP,
DBP, diabetes
2.38 (1.4–4.1) 3.33 (1.6–7.0)
Abbreviations: ACR, albumin/creatinine ratio; BMI, body mass index; CI, confidence
interval; DBP, diastolic blood pressure; PSGN, post-streptococcal glomerulonephritis;
SBP, systolic blood pressure.
Referrent group consists of people without a history of PSGN.
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epidemics, a child appearing ‘puffy’ has sometimes not been
further evaluated. In these settings, too, asymptomatic cases
are entirely missed, although heightened consciousness and
some targeted screening precipitated by symptomatic cases
heralding epidemics result in more case-finding at those
times. Undiagnosed cases probably contribute to some of the
‘unexplained’ albuminuria in community members without a
recognized PSGN history. However, asymptomatic episodes
are likely to be associated with a less serious acute course, as
well as with less marked long-term consequences through
lower levels of permanent nephron loss.
The data support the inclusion of PSGN as one vital factor
in the multideterminant model of albuminuria. Such a model
was first formulated in this community,13 and is conceptually
supported by the ‘multihit’ hypothesis of renal disease later
proposed by Nenoff et al.27 Other factors whose significant
association with albuminuria we have modeled include age,
lower birth weights, skin sores and scabies, non-skin infections
(specifically with Helicobacter pylori), high C-reactive protein
levels, levels of glycemia, lipids, current body weight, and
central fat deposition.13,28 The presence of a persistent specific
anti-streptococcal antibody, evaluated in a limited number of
screened subjects, was also associated with higher levels of
proteinuria, with the effect amplified by concurrent over-
weight or obesity.29 Lower birth weights, skin sores, scabies,
and PSGN are among early-life determinants of kidney
disease. Presumably, presence or establishment of an early
nephron deficit sets the stage for further cascading nephron
loss based on hyperperfusion/hyperfiltration.24 The notable
female predominance in renal disease and renal failure in this
and other remote Aboriginal settings7,13 might be partly
explained by the equal susceptibility of girls and boys to
PSGN, the documented lower birth weights in girls,30 their
greater accrual of body fat as adults, and the lower nephron
endowment in women generally, as demonstrated through
autopsy studies.31,32
PSGN has been called a disease of transition. Previously,
these Aboriginal people lived in small groups, were nomadic,
and did not have permanent dwellings. Now they live in very
crowded, poorly ventilated, poorly maintained dirty houses,
where scabies thrives and Group A streptococci spread easily.
We cannot comment on the occurrence of PSGN before the
observation period, but a community death register and,
more recently, dialysis registries suggest that renal failure has
increased markedly since the late 1970s. This, we propose, is
fuelled in part by PSGN and infections related to crowding,
poor hygiene, and poor nutrition, while phenomena asso-
ciated with lifestyle and health transition, and improved
survival of low-birth-weight infants have also contributed.30
Against this background of precipitating factors, the possi-
bility of a genetic contribution to disease susceptibility is also
being explored.
The frequency of PSGN in this era in a western country is
astonishing. The elimination of scabies, the marker of the
environment in which PSGN and other third-world diseases
flourish, must be a top priority in remote communities.
This is a matter of wholesale improvement across all sectors
such as housing, nutrition, and education. Justification could
be based on cost savings in renal replacement therapy alone.
The imminent trialling of anti-streptococcal vaccine could be
extended to renal outcomes, rather than the exclusive rheu-
matic heart disease endpoints for which it was developed.33
Nonetheless, the virtual elimination of PSGN in westernized
environments was achieved without such a vaccine, and no
less should be expected for Aboriginal people.
MATERIALS AND METHODS
A community-wide health screen was performed from 2004 to
2006 in a remote Australian Aboriginal community with high
rates of renal and cardiovascular disease, on all volunteers aged
X5 years. Assessments included albumin and creatinine con-
centrations on random urine samples. Medical records were
reviewed for notation of episodes of acute PSGN in their past.
Associations of albuminuria with histories of PSGN at least
5 years before screening were evaluated in people aged less than
40 years at screening.
The first diagnosis of PSGN was extracted from review of
the local clinical records. A diagnosis was based on a compatible
clinical picture, defined by urine abnormalities (essential),
accompanied by edema and/or hypertension, and/or compatible
serologic changes, including elevated levels of anti-streptococcal
antibodies and low levels of total hemolytic complement and/or
C3.4 The date of diagnosis had also been noted in all but five
cases.
The earliest documentation of episodes of PSGN in the clinical
records of participants in the screen was in 1970, within a few
years of the arrival of the first pediatrician in the Northern
Territory, Dr Alan Walker. We do not know whether few episodes
occurred earlier, or were not recognized or not recorded. To
minimize failure of case ascertainment in early life, we therefore
restricted the analysis to people who were o40 years of age at time
of screening. That age cutoff also minimizes bias created by
premature mortality in this community, and where, as we have
shown, albuminuria predicts all the causal renal death and much
of the nonrenal natural death.14 Evaluation of the association of
episodes of PSGN with chronic renal disease were confined to
subjects whose most recent episode of PSGN had been at least
5 years before screening, to minimize lingering contributions
of still-recovering acute PSGN episodes to potential urine or renal
functional abnormalities. This requirement necessarily excluded
the five people with PSGN without a recorded date of diagnosis,
and most of the children with a PSGN history who were aged 5–9
years at screening; thus, the youngest age group was not included in
subsequent analyses.
Descriptive statistics are presented as means, standard deviations,
and ranges, or as geometric means and 95% confidence intervals for
continuous variables, or as percentages and 95% confidence
intervals for categorical variables. Comparisons by PSGN status
were made using t-tests or the Wilcoxon rank sums tests for
continuous variables and by w2 test or the Fisher’s exact test for
categorical variables. Logistic regression was used to determine the
association between a history of remote PSGN and specific renal
parameters with separate models developed for each sex. Most
statistical tests were two tailed and the threshold of statistical
significance was Po0.05. Analyses were performed using Stata
version 11.1 statistical software.34
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